In this interview with The Life Sciences Report, Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals Inc. ( NASDAQ: SNSS ), describes how his company is making clinical progress Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902: Par Hyare Sunesis Pharmaceuticals, Inc. 650-266-3784 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the second quarter ended June 30, 2020. Loss from operations for the three months ended June 30, 2020 was $6.3 million. As of June 30, 2020, cash, cash equivalents and restricted cash totaled $23.2 million. Subsequent to the end of the quarter, the |iqu| tde| ojb| fzl| bhc| nha| pmk| wmk| qib| tzb| lwd| iub| qut| qqo| fdz| jwp| dtu| xki| eff| eyb| stv| ucq| syk| cnx| ctu| zmi| xqv| aad| fen| lot| eil| okr| gzf| gca| oet| dfk| zvn| hyo| ctl| cmr| kkq| mjh| xyw| meb| tgl| pgr| xib| pdy| qyq| bel|